Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development. Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right. With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
Saving Sight. Saving Lives. Optos introduced optomap® ultra-widefield (UWF™) retinal imaging to enable eyecare professionals to discover, diagnose, document and treat ocular pathology that may first present in the periphery – pathology which may go undetected using traditional examination techniques and equipment. Our devices image more than 80% or 200˚ of the retina in a single capture in less than ½ second with some offering integrated OCT. More than 800 published and ongoing clinical trials, as well as thousands of case studies and testimonials, show the long-term value of optomap UWF imaging in diagnosis, treatment planning, and patient engagement.